… monotherapy, 45.7% with amlodipine, and 38.3% with placebo. Results of the current pooled
analyses for adverse events in patient subgroups defined by hypertension stage, age, and …

… Subgroup analyses were conducted for the systolic BP control … relevance in older hypertensive
patients and in patients with … , double-blind, placebo-controlled, parallel-group studies …

… Exploratory subgroup analyses were performed to evaluate … , and in Hispanic individuals,
but not in Black patients (Figure … elderly patients reached this systolic target in the amlodipine/…

… or older with a documented diagnosis of systolic hypertension (… of African American patients
who achieved BP goal while … this subgroup analysis confirm previous findings that the BP-…

… 2 placebo-controlled trials of amlodipine/valsartan combination compared with monotherapy
in patients … therapy compared with amlodipine monotherapy in black patients with stage 2 …

… post hoc analyses of the aforementioned placebo-controlled … ITT patient population and in
subgroups of patients with stage … two-thirds of stage 2 patients receiving amlodipine/valsartan …

… Subgroup analyses were also performed according to the … monotherapy with the addition of
HCTZ to either regimen if … : a double-blind placebo-controlled crossover trial with ambulatory …

… ▴ Subgroup analyses of data from the two trials showed that the … with that of amlodipine or
valsartan monotherapy in two randomized, double-blind, placebo-controlled, factorial studies. …

… more difficult to achieve in selected subgroups (eg, elderly patients)Citation7. … combination
in the elderly has also been demonstrated in previously reported placebo-controlled studies…

… initial therapy or in patients who fail to respond to monotherapy. These drug classes … subgroup
analysis of two 8-week, multicenter, randomized, double-blind, placebo-controlled studies …